Key result
Dapagliflozin maintains consistent efficacy and safety across all diuretic subgroups in HFrEF.
Why the study?
Does dapagliflozin maintain consistent efficacy and safety across diuretic subgroups in patients with heart failure and reduced ejection fraction?
Does dapagliflozin maintain consistent efficacy and safety across diuretic subgroups in patients with heart failure and reduced ejection fraction?
Dapagliflozin demonstrates consistent efficacy and safety regardless of baseline diuretic use in patients with HFrEF.
Answers are grounded in this paper and cite their sources.
Supports dapagliflozin use in HFrEF irrespective of diuretic background; confirms broad applicability of DAPA-HF results.
The efficacy and safety of dapagliflozin were consistent across the diuretic subgroups examined in DAPA-HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2020) studied this question. Dapagliflozin demonstrated consistent efficacy and safety across all examined diuretic subgroups in patients with heart failure and reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: